1.

Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Onc...

2.

Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Onc...

3.

Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Onc...

1.

Nationwide population-based cohort study of uterine rupture in Belgium: Results from the Belgian obstetric surveillance system

2.

Nationwide population-based cohort study of uterine rupture in Belgium: Results from the Belgian obstetric surveillance system

3.

Nationwide population-based cohort study of uterine rupture in Belgium: Results from the Belgian obstetric surveillance system

4.

Nationwide population-based cohort study of uterine rupture in Belgium: Results from the Belgian obstetric surveillance system

5.

Nationwide population-based cohort study of uterine rupture in Belgium: Results from the Belgian obstetric surveillance system

1.

Immunogenicity of COVID-19 Vaccination in Patients With Axial Spondyloarthritis: A Monocentric Prospective Belgian Cohort Study.

2.

Immunogenicity of COVID-19 Vaccination in Patients With Axial Spondyloarthritis: A Monocentric Prospective Belgian Cohort Study.

3.

Immunogenicity of COVID-19 Vaccination in Patients With Axial Spondyloarthritis: A Monocentric Prospective Belgian Cohort Study.

1.

Fewer pre-emptive renal transplantations and more rejections in immigrant children compared to native Dutch and Belgian children.

2.

Fewer pre-emptive renal transplantations and more rejections in immigrant children compared to native Dutch and Belgian children.

3.

Fewer pre-emptive renal transplantations and more rejections in immigrant children compared to native Dutch and Belgian children.

4.

Fewer pre-emptive renal transplantations and more rejections in immigrant children compared to native Dutch and Belgian children.

5.

Fewer pre-emptive renal transplantations and more rejections in immigrant children compared to native Dutch and Belgian children.

6.

Fewer pre-emptive renal transplantations and more rejections in immigrant children compared to native Dutch and Belgian children.

7.

Fewer pre-emptive renal transplantations and more rejections in immigrant children compared to native Dutch and Belgian children.

8.

Fewer pre-emptive renal transplantations and more rejections in immigrant children compared to native Dutch and Belgian children.

9.

Fewer pre-emptive renal transplantations and more rejections in immigrant children compared to native Dutch and Belgian children.

1.

Perceived work ability and turnover intentions: a prospective study among Belgian healthcare workers

2.

Perceived work ability and turnover intentions: a prospective study among Belgian healthcare workers

3.

Perceived work ability and turnover intentions: a prospective study among Belgian healthcare workers

4.

Perceived work ability and turnover intentions: a prospective study among Belgian healthcare workers

5.

Perceived work ability and turnover intentions: a prospective study among Belgian healthcare workers

6.

Perceived work ability and turnover intentions: a prospective study among Belgian healthcare workers

7.

Perceived work ability and turnover intentions: a prospective study among Belgian healthcare workers

8.

Perceived work ability and turnover intentions: a prospective study among Belgian healthcare workers

1.

Real-World Efficacy and Safety of Apremilast in Belgian Patients with Psoriatic Arthritis: Results from the Prospective Observational APOLO Study.

2.

Real-World Efficacy and Safety of Apremilast in Belgian Patients with Psoriatic Arthritis: Results from the Prospective Observational APOLO Study.

3.

Real-World Efficacy and Safety of Apremilast in Belgian Patients with Psoriatic Arthritis: Results from the Prospective Observational APOLO Study.

4.

Real-World Efficacy and Safety of Apremilast in Belgian Patients with Psoriatic Arthritis: Results from the Prospective Observational APOLO Study.

5.

Real-World Efficacy and Safety of Apremilast in Belgian Patients with Psoriatic Arthritis: Results from the Prospective Observational APOLO Study.

6.

Real-World Efficacy and Safety of Apremilast in Belgian Patients with Psoriatic Arthritis: Results from the Prospective Observational APOLO Study.

7.

Real-World Efficacy and Safety of Apremilast in Belgian Patients with Psoriatic Arthritis: Results from the Prospective Observational APOLO Study.

8.

Real-World Efficacy and Safety of Apremilast in Belgian Patients with Psoriatic Arthritis: Results from the Prospective Observational APOLO Study.

1.

Instauration et optimisation d'une insulinothérapie en médecine générale : InsuStar, une étude observationnelle prospective belge dans le diabète de type 2 ; Initiating and intensi...

2.

Instauration et optimisation d'une insulinothérapie en médecine générale : InsuStar, une étude observationnelle prospective belge dans le diabète de type 2 ; Initiating and intensi...

3.

Instauration et optimisation d'une insulinothérapie en médecine générale : InsuStar, une étude observationnelle prospective belge dans le diabète de type 2 ; Initiating and intensi...

4.

Instauration et optimisation d'une insulinothérapie en médecine générale : InsuStar, une étude observationnelle prospective belge dans le diabète de type 2 ; Initiating and intensi...

5.

Instauration et optimisation d'une insulinothérapie en médecine générale : InsuStar, une étude observationnelle prospective belge dans le diabète de type 2 ; Initiating and intensi...

1.

Important differences in management policies for children with end-stage renal disease in the Netherlands and Belgium--report from the RICH-Q study.

2.

Important differences in management policies for children with end-stage renal disease in the Netherlands and Belgium--report from the RICH-Q study.

3.

Important differences in management policies for children with end-stage renal disease in the Netherlands and Belgium--report from the RICH-Q study.

4.

Important differences in management policies for children with end-stage renal disease in the Netherlands and Belgium--report from the RICH-Q study.

5.

Important differences in management policies for children with end-stage renal disease in the Netherlands and Belgium--report from the RICH-Q study.

6.

Important differences in management policies for children with end-stage renal disease in the Netherlands and Belgium--report from the RICH-Q study.

7.

Important differences in management policies for children with end-stage renal disease in the Netherlands and Belgium--report from the RICH-Q study.

8.

Important differences in management policies for children with end-stage renal disease in the Netherlands and Belgium--report from the RICH-Q study.

9.

Important differences in management policies for children with end-stage renal disease in the Netherlands and Belgium--report from the RICH-Q study.

1.

Linking clinical and population-based data in older patients with cancer in Belgium: Feasibility and clinical outcomes.

2.

Linking clinical and population-based data in older patients with cancer in Belgium: Feasibility and clinical outcomes.

3.

Linking clinical and population-based data in older patients with cancer in Belgium: Feasibility and clinical outcomes.

4.

Linking clinical and population-based data in older patients with cancer in Belgium: Feasibility and clinical outcomes.

5.

Linking clinical and population-based data in older patients with cancer in Belgium: Feasibility and clinical outcomes.

6.

Linking clinical and population-based data in older patients with cancer in Belgium: Feasibility and clinical outcomes.

7.

Linking clinical and population-based data in older patients with cancer in Belgium: Feasibility and clinical outcomes.

8.

Linking clinical and population-based data in older patients with cancer in Belgium: Feasibility and clinical outcomes.

9.

Linking clinical and population-based data in older patients with cancer in Belgium: Feasibility and clinical outcomes.

1.

SPICT as a predictive tool for risk of 1-year health degradation and death in older patients admitted to the emergency department: a bicentric cohort study in Belgium.

2.

SPICT as a predictive tool for risk of 1-year health degradation and death in older patients admitted to the emergency department: a bicentric cohort study in Belgium.

3.

SPICT as a predictive tool for risk of 1-year health degradation and death in older patients admitted to the emergency department: a bicentric cohort study in Belgium.

4.

SPICT as a predictive tool for risk of 1-year health degradation and death in older patients admitted to the emergency department: a bicentric cohort study in Belgium.

5.

SPICT as a predictive tool for risk of 1-year health degradation and death in older patients admitted to the emergency department: a bicentric cohort study in Belgium.

6.

SPICT as a predictive tool for risk of 1-year health degradation and death in older patients admitted to the emergency department: a bicentric cohort study in Belgium.

7.

SPICT as a predictive tool for risk of 1-year health degradation and death in older patients admitted to the emergency department: a bicentric cohort study in Belgium.